Sulggi A Lee, MD PhD
University of California, San Francisco
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sulggi A Lee, MD PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:43 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04485130 · DISulfiram for COvid-19 (DISCO) TrialUniversity of California, San Francisco · terminated · Covid19 · principal investigator
- Ph4NCT03825536 · Effect of Methamphetamine on Residual Latent HIV Disease StudyUniversity of California, San Francisco · completed · HIV-1-infection, Methamphetamine-dependence · principal investigator
- Ph1NCT02531295 · Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation StudyUniversity of California, San Francisco · terminated · HIV, Human Immunodeficiency Virus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV diseaseR61DA047024 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sulggi Angela Lee · fiscal years 2018 to 2021Named on NCT03825536
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.